These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [CLINICAL RECOMMENDATIONS FOR DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH ESOPHAGEAL AND ESOPHAGOGASTRIC JUNCTION CANCERS]. Bišof V; Juretić A; Stančić-Rokotov D; Rustemović N; Miletić D; Boban M; Omrčen T; Razumović JJ; Pavlović I; Fröbe A; Čonkaš M; Rakušić Z; Gugić D Lijec Vjesn; 2016; 138(9-10):233-9. PubMed ID: 30148543 [TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness in esophagogastric cancer. Knab LM; Belotte J; Munshi HG; Bentrem DJ Cancer Treat Res; 2015; 164():121-42. PubMed ID: 25677022 [TBL] [Abstract][Full Text] [Related]
25. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K; Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671 [TBL] [Abstract][Full Text] [Related]
26. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma. Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530 [TBL] [Abstract][Full Text] [Related]
27. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West. Wilke H; Lordick F; Meyer HJ; Stahl M Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587 [TBL] [Abstract][Full Text] [Related]
28. [Diagnosis and management of gastro-esophageal junction tumor]. Chevallay M; Jung M; Niclauss N; Morel P; Mönig S Rev Med Suisse; 2017 Jun; 13(567):1236-1239. PubMed ID: 28643978 [TBL] [Abstract][Full Text] [Related]
29. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Briasoulis E; Fatouros M; Roukos DH Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806 [No Abstract] [Full Text] [Related]
30. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration. Nakayama I; Ohashi M; Nunobe S Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658 [TBL] [Abstract][Full Text] [Related]
31. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions. Sandler S Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325 [TBL] [Abstract][Full Text] [Related]
32. Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia. Sasako M Expert Rev Anticancer Ther; 2019 Nov; 19(11):939-945. PubMed ID: 31661989 [No Abstract] [Full Text] [Related]
33. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M; Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827 [TBL] [Abstract][Full Text] [Related]
34. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy. Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159 [TBL] [Abstract][Full Text] [Related]
35. Cancer of the gastroesophageal junction: combined modality therapy. Ilson DH Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275 [TBL] [Abstract][Full Text] [Related]
36. Localized adenocarcinoma of the esophagogastric junction--is there a standard of care? Power DG; Reynolds JV Cancer Treat Rev; 2010 Aug; 36(5):400-9. PubMed ID: 20117883 [TBL] [Abstract][Full Text] [Related]
37. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271 [TBL] [Abstract][Full Text] [Related]
38. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Matuschek C; Bölke E; Peiper M; Knoefel WT; Budach W; Erhardt A; Scherer A; Gerber PA; Buhren BA; Gattermann N; Baldus SE; Rusnak E; Shukla V; Orth K Eur J Med Res; 2011 Jun; 16(6):265-74. PubMed ID: 21810561 [TBL] [Abstract][Full Text] [Related]
39. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Hosoda K; Yamashita K; Katada N; Watanabe M Gen Thorac Cardiovasc Surg; 2015 Oct; 63(10):549-56. PubMed ID: 26232357 [TBL] [Abstract][Full Text] [Related]
40. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]